Lotus Pharmaceutical Adjusts Investment Structure, Increases Capital in Singapore Subsidiary by US$18 Million
Lotus Pharmaceutical has decided to adjust its group investment structure by contributing the full ownership of its Japanese subsidiary, Lotus Japan Holdings Co., Ltd., as an in-kind investment of US$18 million to its Singapore subsidiary, Lotus International Pte. Ltd. This move aims to streamline operations and strengthen its international competitiveness in Asia.
📋 Article Processing Timeline
- 📰 Published: May 11, 2026 at 21:56
- 🔍 Collected: May 11, 2026 at 22:32 (35 min after Published)
- 🤖 AI Analyzed: May 11, 2026 at 22:37 (5 min after Collected)
ASEAN Financial Special Report (Total 300 articles)
Central News Agency
Master the New Southbound Policy, look at the economic pulse of ASEAN. Central News Agency's 'Southeast Asia Financial Information Special Network' selects multiple financial headlines from Thailand, Vietnam, Indonesia, Malaysia, the Philippines, and other countries for you daily. Whether it's new government policies, industry trends, or investment opportunities, it allows you to grasp key information instantly, understand the market, and seize business opportunities.
(Central News Agency, Taipei, 11th) Pharmaceutical company Lotus Pharmaceutical's board of directors today resolved that, in response to the adjustment of the group's investment structure, it will contribute the full ownership of its Japanese subsidiary, Lotus Japan Holdings Co., Ltd., as an in-kind investment to its Singapore subsidiary, Lotus International Pte. Ltd., amounting to US$18 million.
Including this transaction, Lotus Pharmaceutical will hold 68.1 million shares of Lotus International Pte. Ltd., totaling NT$2,146,853,125.
Lotus Pharmaceutical's operational headquarters are in Taiwan, with Asian operational bases covering South Korea, Singapore, Thailand, Vietnam, Malaysia, the Philippines, Hong Kong, China, India, and Japan; in terms of R&D and manufacturing, it has production bases in Taiwan and South Korea, and R&D centers in Taiwan and India.
Lotus Pharmaceutical today announced its Q1 financial report, with revenue of NT$8.644 billion, net profit attributable to owners of the parent company of NT$567 million, and earnings per share of NT$2.18. 1150511
Choose to stand with facts, every sponsorship you make is a force to protect press freedom.
Download the Central News Agency 'First-hand News' APP to get the latest news instantly.
Text, images, and audio/video on this website may not be reproduced, publicly broadcast, or publicly transmitted and used without authorization.
Central News Agency
Master the New Southbound Policy, look at the economic pulse of ASEAN. Central News Agency's 'Southeast Asia Financial Information Special Network' selects multiple financial headlines from Thailand, Vietnam, Indonesia, Malaysia, the Philippines, and other countries for you daily. Whether it's new government policies, industry trends, or investment opportunities, it allows you to grasp key information instantly, understand the market, and seize business opportunities.
(Central News Agency, Taipei, 11th) Pharmaceutical company Lotus Pharmaceutical's board of directors today resolved that, in response to the adjustment of the group's investment structure, it will contribute the full ownership of its Japanese subsidiary, Lotus Japan Holdings Co., Ltd., as an in-kind investment to its Singapore subsidiary, Lotus International Pte. Ltd., amounting to US$18 million.
Including this transaction, Lotus Pharmaceutical will hold 68.1 million shares of Lotus International Pte. Ltd., totaling NT$2,146,853,125.
Lotus Pharmaceutical's operational headquarters are in Taiwan, with Asian operational bases covering South Korea, Singapore, Thailand, Vietnam, Malaysia, the Philippines, Hong Kong, China, India, and Japan; in terms of R&D and manufacturing, it has production bases in Taiwan and South Korea, and R&D centers in Taiwan and India.
Lotus Pharmaceutical today announced its Q1 financial report, with revenue of NT$8.644 billion, net profit attributable to owners of the parent company of NT$567 million, and earnings per share of NT$2.18. 1150511
Choose to stand with facts, every sponsorship you make is a force to protect press freedom.
Download the Central News Agency 'First-hand News' APP to get the latest news instantly.
Text, images, and audio/video on this website may not be reproduced, publicly broadcast, or publicly transmitted and used without authorization.